The results of the above trials were used by the American Diabetes Association and the European Association for the Study of Diabetes in a consensus report, and it was suggested that in the treatment of patients with DM and cardiovascular disease, a glucagon-like peptide-1 (GLP-1) receptor agonist or a SGLT2 inhibitor should be used as an extra treatment in standard therapy with metformin [157]. This evidence concerns the gene SLC5A2 and cardiovascular disorder.